Haywood G A, Varini R, Osmancik P, Cireddu M, Caldwell J, Chaudhry M A, Loubani M, Della Bella P, Lapenna E, Budera P, Dalrymple-Hay M
University Hospitals, Plymouth, UK.
Cardiocenter, University Hospital Kralovske Vinohrady, Prague, Czechia.
Int J Cardiol Heart Vasc. 2020 Jan 6;26:100459. doi: 10.1016/j.ijcha.2019.100459. eCollection 2020 Feb.
The management of non-paroxysmal atrial fibrillation (AF) remains controversial. We examined the efficacy and safety of the 2 stage Hybrid AF ablation approach by analysing the largest series of this technique reported so far.
The approach aims to electrically isolate the left atrial posterior wall incorporating the pulmonary veins ('box-set'pattern). An initial video-assisted thoracoscopic (VATS) epicardial ablation is followed after a minimum of 8 weeks by endocardial radiofrequency catheter ablation.
Of 175 patients from 4 European cardiothoracic centers, who underwent the surgical (COBRA Fusion, AtriCure Inc) 1st stage ablation, 166 went on to complete 2nd stage catheter ablation. At median follow up of 18 months post 2nd stage procedure 93/166 (56%) had remained free of AF or atrial tachycardia (AT) recurrence off antiarrhythmic drugs. 110/175 62.9% were in sinus rhythm off all antiarrhythmic drugs at last clinic follow-up (132/175 75.4% including those on antiarrhythmic drugs). 18 patients (10.8%) underwent a further re-do ablation (mean of 1.1 ablations per patient) 105/166 (63%) remained free of AF/AT recurrence off antiarrhythmic drugs following last ablation procedure.Latterly, ILRs have been implanted in patients (n = 56); 60% have remained fully arrhythmia free and 80% have shown AF burden < 5% at a median 14 months follow-up [IQR: 13.5 (8-21.5)]. Only 10.9% have reverted to persistent AF. 5 patients (2.9%) had a perioperative stroke and 4 patients (2.3%) exhibited persistent weakness of the right hemidiaphragm following stage 1 VATS epicardial ablation. One patient died following stroke (overall mortality 0.6%).
In patients with non-paroxysmal AF with unfavourable characteristics for catheter ablation, the staged hybrid approach results in acceptable levels of freedom from recurrent atrial arrhythmia, however, complication rates are higher than with catheter ablation alone.
非阵发性心房颤动(AF)的治疗仍存在争议。我们通过分析迄今为止报道的该技术的最大系列病例,研究了两阶段杂交AF消融方法的疗效和安全性。
该方法旨在通过电隔离包含肺静脉的左心房后壁(“盒式”模式)。最初进行电视辅助胸腔镜(VATS)心外膜消融,至少8周后进行心内膜射频导管消融。
来自4个欧洲心胸中心的175例患者接受了手术(COBRA Fusion,AtriCure Inc)第一阶段消融,其中166例继续完成第二阶段导管消融。在第二阶段手术后的中位随访18个月时,93/166(56%)患者在停用抗心律失常药物后未出现AF或房性心动过速(AT)复发。在最后一次门诊随访时,110/175(62.9%)患者在停用所有抗心律失常药物后处于窦性心律(132/175,75.4%,包括服用抗心律失常药物的患者)。18例患者(10.8%)接受了再次消融(平均每位患者1.1次消融),105/166(63%)患者在最后一次消融手术后停用抗心律失常药物后未出现AF/AT复发。最近,已在患者(n = 56)中植入了植入式心律记录仪(ILR);在中位随访14个月时,60%的患者完全无心律失常,80%的患者房颤负荷<5%[四分位间距:13.5(8 - 21.5)]。只有10.9%的患者恢复为持续性房颤。5例患者(2.9%)发生围手术期卒中,4例患者(2.3%)在第一阶段VATS心外膜消融后出现右侧膈肌持续无力。1例患者因卒中死亡(总死亡率0.6%)。
对于导管消融特征不佳的非阵发性AF患者,分期杂交方法可使复发性房性心律失常的自由度达到可接受水平,然而,并发症发生率高于单纯导管消融。